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Objective:  To evaluate the association between metformin use and anaemia risk in type 2 
diabetes, and the time-course for this, in randomised controlled trial (RCT) and real-world 
population data. 
Research design and methods: Anaemia was defined as a haemoglobin measure less than 
11g/dL. In RCTs (ADOPT (n=3,967), UKPDS (n=1,473)), logistic regression was used to 
model anaemia risk and non-linear mixed models for change in haematological parameters.In 
the observational GoDARTS population (n=3,485), discrete-time failure analysis was used to 
model the effect of cumulative metformin exposure on anaemia risk.   
Results: In ADOPT, compared with sulfonylureas, the odds ratio(OR)(95%CI) for anaemia 
was 1.93(1.10,3.38) for metformin and 4.18(2.50,7.00) for thiazolidinediones. In UKPDS, 
compared with diet, the OR(95%CI) was 3.40(1.98,5.83) for metformin, 0.96(0.57,1.62) for 
sulfonylureas and 1.08(0.62,1.87) for insulin.  
In ADOPT, haemoglobin and haematocrit dropped following metformin initiation by six 
months, with no further decrease after three years. In UKPDS, haemoglobin fell by three years 
in the metformin group compared to other treatments. At years six and nine, haemoglobin was 
reduced in all treatment groups, with no greater difference seen in the metformin group. In 
GoDARTS, each 1g/day of metformin use was associated with a 2% higher annual risk of 
anaemia.    
Conclusions: Metformin use is associated with early risk of anaemia in individuals with type 
2 diabetes, a finding consistent across two RCTs and replicated in one real-world study. The 
mechanism for this early fall in haemoglobin is uncertain, but given the time course is unlikely 





Anaemia is a common finding in individuals with type 2 diabetes (1). Metformin is the first-
line therapy for treatment of type 2 diabetes in most individuals, and the most widely prescribed 
oral antidiabetic medication. A recent meta-analysis reviewed all available studies on 
associations between metformin use and vitamin B12 levels, anaemia, and neuropathy in 
individuals with type 2 diabetes (2). The meta-analysis confirmed individuals taking metformin 
had a significantly higher risk of vitamin B12 deficiency than those not taking metformin, and 
significantly lower serum B12 concentrations, which depended on dose and duration of 
treatment. Although this meta-analysis reported no association between metformin use and 
anaemia risk, it is important to note that there were only four eligible studies and most of these 
were cross-sectional or case-control which did not have anaemia as their primary endpoint (3-
6).  In contrast, the DPP Outcomes Study showed metformin use in individuals with impaired 
glucose tolerance was associated with an increased risk of anaemia at five years, independent 
of vitamin B12 status (7).  There is therefore uncertainty about whether metformin causes 
anaemia, and whether or not this is mediated by B12 deficiency in metformin treated 
individuals with type 2 diabetes. 
The aims of this study were firstly to use randomised controlled trial (RCT) data with repeated 
haematological measures to determine if there is an association between metformin use and 
anaemia risk in type 2 diabetes, and, if so, what is the time-frame for this? Secondly, to quantify 
risk in a real-world setting, by examining whether cumulative exposure to metformin is 
associated with an increase in incidence of anaemia using routinely collected clinical data. 
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RESEARCH DESIGN AND METHODS 
Data sources 
Three datasets were analysed: two from randomised controlled trials (A Diabetes Outcome 
Progression Trial [ADOPT], UK Prospective Diabetes Study [UKPDS] and one from routine 
clinical data Genetics of Diabetes Audit and Research in Tayside Scotland [GoDARTS]). 
ADOPT was a trial in which 4,351 drug naïve individuals recently diagnosed with type 2 
diabetes were assigned randomly to thiazolidinediones (TZDs), metformin or sulfonylurea 
monotherapy and followed up for five years (8). Haematological measures were collected at 
baseline, six months, one year and annually thereafter.  
UKPDS was a trial in which 4,209 individuals with newly diagnosed type 2 diabetes were 
randomised to receive a conventional (diet) or intensive glycaemic management strategy 
(insulin, sulfonylurea or metformin) (9; 10).  Haematological measures were collected at 
baseline, three, six and nine year follow up. 
GoDARTS is a large population-based cohort of approximately 10,000 individuals with type 2 
diabetes, with comprehensive electronic medical records containing detailed information on all 
encashed prescriptions (including daily dose and adherence) from 1994 onwards in Tayside 





Definition of anaemia 
Haemoglobin (Hb) was the outcome variable. It was used as a continuous variable in ADOPT 
and UKPDS to investigate change over time, and recoded as a binary outcome for estimating 
the risk of anaemia in all three studies. The anaemia endpoint was defined as the first Hb 
measure less than 11g/dL in both males and females (the moderate anaemia definition used by 
the World Health Organization [WHO]) following diabetes diagnosis.  Individuals with 
prevalent anaemia at baseline (diagnosis) (defined by WHO as Hb less than 12g/dL in females 
and 13g/dL in males) were excluded from this analysis. 
 
Study Populations 
ADOPT: All participants in the intention to treat subset were eligible for the study. Individuals 
with missing baseline covariates, or anaemia at baseline were excluded.  
UKPDS: All participants with greater than 120% ideal body weight in the 15 centres recruited 
prior to 1988 were eligible for the study (9). Individuals with missing baseline covariates or 
anaemia at baseline were excluded. 
GoDARTS: Individuals with type 2 diabetes diagnosed on or after 1st January 1996 were 
eligible for the study, thus ensuring sufficient prescribing information and Hb measurements. 
In addition, individuals were required to have a baseline Hb measure (defined as closest 
measure to type 2 diabetes diagnosis up to one year prior) and no anaemia at baseline. The 
study period for eligible individuals was defined as time from type 2 diagnosis (baseline) until 
first anaemia event, death, leaving area or end of follow-up (30th September 2015), whichever 





ADOPT and UKPDS:  The risk of moderate anaemia at any time point during the trials was 
modelled using logistic regression. The reference groups for treatment were sulfonylureas and 
diet for ADOPT and UKPDS, respectively. Covariates included in the model were sex, baseline 
age, Hb, eGFR and BMI.   
Haematological changes over time were modelled using non-linear mixed models. Hb was 
modelled in ADOPT and UKPDS. Haematocrit (Hct) was modelled in ADOPT, and packed 
cell volume (PCV) was modelled in UKPDS as a proxy for Hct which was not available. Hb 
adjusted for Hct (ADOPT) or PCV (UKPDS) was also modelled to assess whether these were 
temporally related. In addition, mean corpuscular volume (MCV) was modelled in ADOPT. 
Data are presented as plots of predictions of the fixed effects for each treatment.  
GoDARTS:  Discrete time survival analysis was used to evaluate the effects of cumulative drug 
exposure. This model is set up as a logistic regression in which each individual contributes one 
observation for each 28-day time interval during the study period. A data matrix was generated 
with one row for each individual under observation in each time interval, and columns 
specifying event status (coded as binary), fixed and time dependent covariates at the start of 
each time interval. 
Exposure to each diabetes drug class (metformin, sulfonylureas, insulin, TZDs, acarbose, 
glucagon-like peptide receptor agonist (GLP-1 RA), dipeptidyl peptidase-4 inhibitor (DPP4i), 
glinide and SGLT2i inhibitor (SGLT2i)) was calculated from the date and intended duration of 
each prescription, but gaps between prescriptions did not accumulate exposure, therefore 
adherence is accounted for in the model. Cumulative exposure of each drug class was 
calculated as the sum of all earlier intervals. If the drug was discontinued during the study the 
cumulative exposure was still carried forward to subsequent time intervals. 
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Age at diabetes diagnosis, sex, baseline Hb, calendar year of diabetes diagnosis and social 
deprivation (coded as 1-5 with 1 most deprived and 5 least deprived) were included as fixed 
covariates. Time from diabetes diagnosis was included as a time dependent covariate. In 
addition, we considered cumulative exposure to metformin in terms of total dose.  BMI and 
eGFR were included as time dependent covariates in a sub group of individuals with these data 
available. 
Pharmacoepidemiological studies are prone to allocation bias. To be satisfied that an estimate 
of a drug’s potential causal effect cannot be due to time invariant between-person confounding 
we include two time-updated terms for each drug class: one for ever-exposure and one for 
cumulative exposure. We focus the inference of causality on the cumulative term (12). The 
terms for ever-exposure and cumulative exposure can be given a visual representation by 
plotting a regression line through the unadjusted rates of anaemia grouped by cumulative 
metformin exposure, representing the linear effect of cumulative exposure. The difference 
between the data point for the unexposed time (x=0) and the estimated regression line at this 
point gives the magnitude of the ever-exposed term. This is the sum of any immediate stepwise 
effect of metformin and any difference in prior anaemia risk in the never-users vs. ever-users 
of metformin.   
 
GoDARTS analysis was conducted using SAS 9.4 software. ADOPT and UKPDS analyses 








RCT datasets (ADOPT and UKPDS) 
Study populations and anaemia rates 
In ADOPT, from 4127 individuals in the intention-to-treat population, 153 were anaemic at 
baseline, and a further 7 had missing covariate data, leaving 3967 individuals in the study 
population (mean(sd) Hb 14.5(1.1) g/dL, age 56.6(10.0) with 58.9% male). There were 1,343 
metformin, 1,289 sulfonylurea and 1,335 TZD users, with anaemia event rates of 38(2.8%), 
19(1.5%) and 76(5.7%) respectively over the five-year follow up period. 
In UKPDS, from 1704 individuals, 52 were anaemic at baseline, and a further 179 had missing 
covariate data, leaving 1473 individuals in the study population (mean(sd) Hb 15.1(1.2) g/dL, 
age 52.8 (8.1) with 47.1% male). There were 300 metformin, 461 sulfonylurea, 360 insulin and 
352 diet treated individuals, with anaemia event rates of 19(6.3%), 5(1.1%), 9(2.5%) and 
6(1.7%) respectively over the nine-year follow up period. 
 
Logistic regression model for anaemia risk 
The results of the logistic regression for risk of moderate anaemia are presented in 
supplementary tables 1 and 2 for ADOPT and UKPDS respectively. In ADOPT the adjusted 
odds ratio (OR), with sulfonylureas as the reference group, was 1.93(1.10,3.38) for metformin 
and 4.18(2.50,7.00) for TZDs. Other predictors of moderate anaemia risk were older age, lower 
baseline Hb and male sex.  
In UKPDS the adjusted OR, with diet as the reference group, was 4.42(2.28,8.57) for 
metformin, 0.53(0.19,1.48) for sulfonylureas and 1.79(0.73,4.42) for insulin. In addition, lower 





Non-linear mixed model for haemoglobin change over time 
The plots of the prediction of the fixed effects from the non-linear mixed model for each 
treatment group over time are presented in Figure 1. 
In ADOPT, there was an immediate drop from baseline (by first measurement at 6 months) in 
Hb (Figure 1a) in both the metformin and TZD arms. The effect was much larger with TZD 
treatment but the metformin treatment arm followed a similar pattern. Hct fell in a similar 
pattern to that seen for Hb after both metformin and TZD treatment (Figure 1b), and this 
reduction in Hct completely mediated the fall in Hb (Figure 1c).  There was no further Hb 
decrease in ADOPT between 3 and 5 years; at 5 years mean Hb was 0.42 (0.20,0.65) g/dL 
lower in the metformin treated arm than the sulfonylurea treated arm. There was a significant 
downward linear trend in MCV over the 5 years in the metformin treatment arm (p<0.0001) 
but no significant trend in the TZD or sulfonylurea arms (Supplementary Figure 1).   
In UKPDS, there was also a post-baseline reduction in Hb when first measured (at 3 years) in 
those randomised to metformin compared with all other treatments (Figure 1d), with the Hb 
0.49(0.41,0.57) g/dL lower that those diet treated.  Hb fell in all treatment groups at years 6 
and 9 but with no greater further fall seen in the metformin vs. diet treated group (0.49(1.64, 
2.62) vs. (0.50(1.71,2.72) g/dL fall from 3 to 9 years). Similar to ADOPT, the PCV (proxy for 
Hct) also fell with metformin treatment (Figure 1e), and adjustment for the fall in PCV largely 





Routine Clinical Dataset (GoDARTS) 
Derivation of study population 
From a total of 6440 individuals, 3765(58%) had a baseline Hb measure. Of these, 280 were 
excluded as they were anaemic at diagnosis, leaving 3485 individuals for analysis. A 
comparison of characteristics of individuals included and excluded in the study is presented in 
Supplementary Table 3. Individuals excluded due to missing baseline Hb measure were 
younger, with a higher proportion of males. However, individuals excluded due to anaemia at 
baseline were older, with a higher proportion of females. The final study population was older 
than the overall type 2 diabetes population (mean(sd) 62.7(10.6) vs. 61.8(11.0) years at 
diagnosis respectively, p=0.0005) with no difference in proportion of males and females 
(55.5% males in final study population), and mean(sd) Hb 14.7(1.2) g/dL. 
 
Comparison of exposed and unexposed individuals 
Of the 3485 individuals in the study, 2487 had accumulated some exposure to metformin by 
the end of follow-up. Table 1 shows the comparison of characteristics at diabetes diagnosis 
between exposed and unexposed individuals. Ever-users of metformin were younger, more 
socially deprived, with a higher proportion of males, higher Hb, BMI and eGFR.  
 
Study period and outcome 
A total of 1458 (41.8%) individuals had a moderate anaemia event during the follow up period: 
745 in current users, 194 in ex-users and 519 in never-users. The median (IQR) follow up time 
was 8.3(5.0,11.5) years, number of Hb measures per individual in the model was 11(6,20) and 





Effects of cumulative metformin exposure 
Figure 2 shows the unadjusted rates of anaemia by cumulative exposure to metformin 
standardised (within 10-year age bands) to the age distribution (over all person-years) of the 
whole study population. With increasing cumulative exposure there is a higher risk of moderate 
anaemia in metformin users, which is linear after an initial high rate in the first year.  As ever-
users were younger with higher Hb at diagnosis (Table 1) it is unlikely that this group of 
individuals were at higher prior risk of anaemia. It is more likely that this initial greater risk of 
anaemia with metformin can be attributed to an immediate effect of metformin on Hb, 
particularly in light of the ADOPT data where we see a significant change at 6 months (Figure 
1a).  
 
Discrete-time failure model 
The results for the discrete time failure analysis are presented in Table 2. In a simple model 
(model 1) with no diabetes drugs included, older age, longer duration of diabetes, lower 
baseline Hb, and higher social deprivation were associated with higher anaemia risk. There was 
no difference by sex or calendar year of diagnosis, so these covariates were not included in 
subsequent models.  In model 2a, cumulative exposure and ever-exposure to metformin were 
added.  The OR per year of cumulative exposure to metformin was 1.05(1.02,1.08). In model 
2b cumulative metformin exposure is expressed as total dose (1.02(1.01,1.04) per one year of 
1 gram per day). The results of adjusting for all diabetes drug classes are presented in model 3, 
and the association of cumulative metformin with moderate anaemia risk remains. In addition, 
there was an association between cumulative exposure to SGLT2i inhibitors and lower risk of 
moderate anaemia (OR 95%CI 0.46[0.36,0.59]). 
For a subgroup of patients where longitudinal measures of BMI (n=3335) and eGFR (n=2920) 
were available, these were added to the model as time dependent covariates. BMI was not 
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significantly associated with moderate anaemia risk (data not shown). However lower eGFR 





In this study we show for the first time that metformin use is associated with risk of moderate 
anaemia in individuals with type 2 diabetes, and that this finding is consistent across two RCTs 
and replicated in one real-world study of routinely collected data. Furthermore, in the large, 
observational, population-based study with a maximum follow-up period of almost 20 years, 
we show that each 1g/day of metformin use was associated with a 2% higher risk of moderate 
anaemia per year.  
 
Moderate anaemia risk with metformin treatment in ADOPT and UKPDS 
In the ADOPT study we observe the well-described early reduction in Hb seen with initiation 
of TZD treatment (an effect seen pre-marketing and included in the summary of product 
characteristics https://www.medicines.org.uk/emc/medicine/4236). We observe a similar 
pattern in the metformin treated group in ADOPT with an early fall in Hb, with no subsequent 
change after the first 2 years.  These early changes in Hb (translated into moderate anaemia 
events) are matched by findings, albeit observational as opposed to trials, in the real world 
GoDARTS data.   Similarly, in UKPDS the main difference in Hb between the metformin and 
other treatment arms had occurred by the first measurement at 3 years.  The finding in ADOPT, 
and to a large extent in UKPDS, that the fall in Hct (PCV) mirrors the fall in Hb is consistent 
with the anaemia being caused by either a reduction in red cell mass, or an increase in plasma 
volume, or both.  The fall in Hct (and Hb) seen with the TZDs is usually attributed to fluid 
retention and haemodilution, although other mechanisms have been proposed, such as a 
reduction in erythropoiesis due to either a direct effect on the bone marrow or secondary to 
lowering insulin levels (13).  For metformin, it is not possible to infer a mechanism for the 
early reduction in Hb we observed in the data we had access to.  In UKPDS, we show no 
treatment-specific effect of metformin on plasma sodium, albumin, urea, white blood cell 
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count, or aspartate amino transferase (AST) (data not shown) that might collectively point to 
haemodilution, bone marrow suppression or haemolysis.   However, it seems unlikely that the 
mechanism for these early changes in Hb is secondary to B12 deficiency, as individuals should 
have enough B12 stored to last for between two to five years (3). Furthermore, the MCV during 
the 5 year ADOPT study did not increase with metformin treatment (Supplementary Figure 
1), and in the GoDARTS study, of those who developed anaemia in the metformin exposed 
group compared with the non-metformin exposed group, microcytic anaemia was more 
frequent (12.1% vs. 7.3%) and macrocytic less frequent (7.6% vs. 12.3%) (data not shown), 
suggesting that the anaemia is not caused by B12 deficiency.’ 
 
Predictors of moderate anaemia risk in GoDARTS 
In the GoDARTS discrete-time failure model we confirm the known predictors of anaemia risk 
in type 2 diabetes, namely older age, longer duration of diabetes, lower baseline Hb and lower 
eGFR (measured time dependently) adding external validity to our model. 
The association between cumulative SGLT2i exposure and an apparent ‘protective’ effect on 
anaemia risk is in line with RCT findings from The Empagliflozin Cardiovascular Outcome 
Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME) study (14), which 
showed that Hct increases soon after initiation of SGLT2i therapy, and remains elevated for 
duration of treatment. Elevation of Hct has generally been interpreted as indicating 
haemoconcentration due to the diuretic effect of SGLT2i.  
It is perhaps surprising given the ADOPT results that cumulative exposure of TZD was not 
associated with anaemia risk in GoDARTS. This is most likely an artifact of the model, given 
metformin is the first line drug for most individuals, and the study outcome is time to incident 
anaemia, therefore susceptible individuals are more likely to experience an event during their 




Overall anaemia rates  
The overall moderate anaemia rates for the GoDARTS, ADOPT and UKPDS studies were 
41.8, 3.4 and 2.2% respectively. The obvious reasons for the large difference between the real-
world data and the trials are the GoDARTS population are older at diagnosis and followed up 
for longer with a mean(sd) age at diagnosis 62.7(10.6) vs. 52.8 (8.1) and 56.6 (10.0) in UKPDS 
and ADOPT respectively, and a median (IQR) study duration of 8.3(5.0,11.5) compared with 
a maximum 5 years follow up in ADOPT and 9 years in UKPDS. In addition, Hb was measured 
more frequently in the GoDARTS population due to the observational nature of the study, 
where all routinely collected measures were included, resulting in a median(IQR) number of 
Hb measures per individual of 11(6, 20) compared with a maximum of 4 and 7 in UKPDS and 
ADOPT respectively. Thus increasing the chances of a moderate anaemia event being detected. 
In addition, those patients in ADOPT or UKPDS who develop anaemia do not automatically 
drop out of the analysis and could be treated, thus potentially explaining the difference between 
the persisting risk of anaemia with metformin in the observational GoDARTS study compared 
to in the ADOPT RCT.However, it is important to note that in the GoDARTS study we only 
included 54% of the population, as a baseline Hb was required (characteristics of included and 
excluded individuals are provided in Supplementary Table 3) and these individuals would be 
expected to have been at a greater risk of anaemia (by virtue of it being requested by health 






The main limitation of the reported studies is the lack of B12 measurement and lack of other 
data to help point to a mechanism mediating the early reduction in Hb caused by metformin 
treatment.  Careful studies, assessing water balance and red cell production and turnover are 
warranted to better understand how metformin is causing a reduction in Hb. 
A post hoc analysis of RCT data may be considered a limitation. However, in the absence of a 
specifically designed prospective study there are very few RCTs of metformin, ADOPT and 





In this study, including data from two RCTs, albeit post hoc, we have shown that metformin 
consistently causes an early reduction in Hb and increases rates of moderate anaemia.  The 
absolute Hb reductions are not large (0.5g/dL at 5 years with ADOPT, 0.5g/dL at 3 years with 
UKPDS) although this does translate to a large increase in moderate anaemia rates, with an 
overall effect in the real-world population study of a 2% increase risk of anaemia per year per 
1g/day of metformin; greater in the first year.  As the mechanisms for metformin-related 
moderate anaemia are unknown, the effects are modest and the benefits of metformin are 
proven, we would not in any way advocate avoidance or discontinuation of metformin, even in 
patients with anaemia, but a reduction in Hb in the first few years after initiation of metformin 
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Table 1: Comparison of characteristics at diabetes diagnosis between those never-users 
and eventual users of metformin 
 Metformin user during study  
 Never Ever P 
n 998 2487  
Age (years) 68.3(10.0) 60.5(10.1) <.0001 
% males 50% 57.7% <.0001 
Year of diagnosis 2005(4.5) 2003.4(3.8) <.0001 
Social deprivation:    
1 (most deprived) 26.1% 27.7%  
2 20.5% 22.2%  
3 15.1% 16.6%  
4 19.4% 16.9%  
5 18.9% 16.7% 0.0301 
Hb (g/dL):    
All 14.3(1.2) 14.8(1.2) <.0001 
Males 15.0(1.1) 15.3(1.1) <.0001 
Females 13.7(1.0) 14.1(1.0) <.0001 
BMI(kg/m2) 30.6(5.7) 32.5(6.1) <.0001 
eGFR (ml/min per 1.732) 75.2(20.4) 87.5(18.3) <.0001 
Data are presented as means(sd) or %; Comparisons are t-test for continuous and chi-square 





Table 2: Discrete-time failure models for moderate anaemia in GoDARTS 
 OR 95% CI P 
Model 1:    
Age at diagnosis (per 1 year) 1.05 1.04,1.05 <.0001 
Time from diagnosis (per 1 year) 1.11 1.09,1.12 <.0001 
Calendar year of diagnosis (per 1 year) 0.99 0.98,1.01 0.8405 
Hb at diagnosis (per 1g/dL) 0.71 0.67,0.75 <.0001 
Females (vs. Males) 1.05 0.94,1.18 0.3841 
Social deprivation (per 1 category (most deprived lowest)) 0.96 0.93,0.99 0.0285 
Model 2a:    
Age at diagnosis (per 1 year) 1.05 1.04,1.06 <.0001 
Time from diagnosis (per 1 year) 1.08 1.06,1.10 <.0001 
Hb at diagnosis (per 1g/dL) 0.70 0.66,0.73 <.0001 
Social deprivation (per 1 category (most deprived lowest))  0.96 0.93,0.99 0.0396 
Ever metformin 1.12 0.98,1.28 0.1045 
Cumulative metformin ( per 1 year) 1.05 1.02,1.08 0.0002 
Model 2b:    
Age at diagnosis (per 1 year) 1.05 1.04,1.06 <.0001 
Time from diagnosis (per 1 year) 1.08 1.06,1.10 <.0001 
Hb at diagnosis (per 1g/dL) 0.69 0.66,0.73 <.0001 
Social deprivation (per 1 category (most deprived lowest))  0.96 0.93,0.99 0.0366 
Ever metformin 1.16 1.02,1.32 0.0224 
Cumulative metformin dose (per 1 year of 1g daily) 1.02 1.01,1.04 0.0001 
Model 3:    
Age at diagnosis (per 1 year) 1.05 1.04,1.06 <.0001 
Time from diagnosis (per 1 year) 1.07 1.05,1.09 <.0001 
Hb at diagnosis (per 1g/dL) 0.69 0.65,0.73 <.0001 
Social deprivation (per 1 category (most deprived lowest))  0.96 0.93,0.99 0.0440 
Ever metformin 1.09 0.95,1.25 0.2217 
Ever sulfonylurea 1.04 0.90,1.21 0.5668 
Ever TZD 1.05 0.83,1.32 0.6768 
Ever insulin 1.43 1.12,1.83 0.0043 
Ever GLP-1 RA 0.51 0.25,1.03 0.0588 
Ever DPP4i 0.83 0.58,1.18 0.2953 
Ever SGLT2i 0.55 0.08,3.96 0.5562 
Ever glinide 0.89 0.40,2.01 0.7825 
Ever acarbose 0.82 0.37,1.82 0.6225 
Cumulative metformin (per 1 year) 1.06 1.03,1.08 <.0001 
Cumulative sulfonylurea (per 1 year) 1.01 0.98,1.04 0.5404 
Cumulative TZD ( per 1 year) 0.99 0.92,1.07 0.9082 
Cumulative insulin (per 1 year) 0.98 0.93,1.04 0.5254 
Cumulative GLP-1 RA (per 1 year) 1.10 0.85,1.44 0.4689 
Cumulative DPP4i (per 1 year) 0.95 0.77,1.17 0.6307 
Cumulative SGLT2i ( per 1 year) 0.46 0.36,0.59 <.0001 
Cumulative glinide (per 1 year) 1.02 0.70,1.48 0.9307 
Cumulative acarbose (per 1 year) 0.91 0.58,1.42 0.6710 
Model 4:    
Age at diagnosis (per 1 year) 1.03 1.02,1.04 <.0001 
Time from diagnosis (per 1 year) 1.05 1.03,1.08 <.0001 
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Hb at diagnosis (per 1g/dL) 0.70 0.66,0.74 <.0001 
Social deprivation (per 1 category (most deprived lowest))  0.97 0.93,1.01 0.1906 
eGFR (per 1ml/min per 1.732) 0.98 0.98,0.99 <.0001 
Ever metformin 1.16 0.99,1.37 0.0760 
Ever sulfonylurea 0.99 0.84,1.18 0.9451 
Ever TZD 1.04 0.80,1.36 0.7593 
Ever insulin 1.31 0.99,1.72 0.0525 
Ever GLP-1 RA 0.71 0.32,1.57 0.3992 
Ever DPP4i 1.00 0.67,1.50 0.9947 
Ever SGLT2i 0.96 0.13,6.96 0.9644 
Ever glinide 0.55 0.20,1.50 0.2428 
Ever acarbose 0.91 0.41,2.03 0.8132 
Cumulative metformin (per 1 year) 1.06 1.02,1.09 0.0006 
Cumulative sulfonylurea (per 1 year) 1.00 0.97,1.04 0.8184 
Cumulative TZD ( per 1 year) 0.98 0.90,1.07 0.6533 
Cumulative insulin (per 1 year) 0.99 0.93,1.05 0.6753 
Cumulative GLP-1 RA ( per 1 year) 1.06 0.79,1.43 0.6876 
Cumulative DPP4i (per 1 year) 0.88 0.69,1.11 0.2754 
Cumulative SGLT2i (per 1 year) 0.40 0.26,0.62 <.0001 
Cumulative glinide (per 1 year) 1.20 0.83,1.72 0.3352 







Figure 1: Plots of haematological changes over time using non-linear mixed models. Data are 
presented as plots of predictions of the fixed effects for each treatment at each study visit.  A: 
ADOPT trial: Hb. B: ADOPT trial: Hct. C: ADOPT trial: Hb adjusted for Hct. D: UKPDS trial: 
Hb. E: UKPDS trial: PCV. F: UKPDS trial: Hb adjusted for PCV 
Figure 2: Plot of unadjusted rates of anaemia by cumulative exposure to metformin 
standardised (within 10-year age bands) to the age distribution (over all person-years) of the 
whole study population. The terms for ever-exposure and cumulative exposure were given a 
visual representation by plotting a regression line through the unadjusted rates of anaemia 
grouped by cumulative metformin exposure, representing the linear effect of cumulative 
exposure.  
 
